Open AccessTen‐year follow‐up of skin‐sparing mastectomy followed by immediate breast reconstruction
Author(s) -
Romics L.,
Chew B. K.,
WeilerMithoff E.,
Doughty J. C.,
Brown I. M.,
Stallard S.,
Wilson C. R.,
Mallon E. A.,
George W. D.
Publication year - 2012
Publication title -
british journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.202
H-Index - 201
eISSN - 1365-2168
pISSN - 0007-1323
DOI - 10.1002/bjs.8704
Subject(s) - medicine , mastectomy , lumpectomy , surgery , breast cancer , stage (stratigraphy) , ductal carcinoma , medical record , breast reconstruction , retrospective cohort study , cancer , paleontology , biology
Abstract Background: The oncological safety of skin‐sparing mastectomy (SSM) followed by immediate breast reconstruction (IBR) is debated owing to a presumed compromise in the completeness of mastectomy. Current evidence is poor as it is based mostly on short‐term follow‐up data from highly selected patients. Methods: A prospectively maintained institutional database was searched to identify patients who underwent SSM and IBR between 1995 and 2000. A retrospective review of medical records was carried out, including only patients with ductal carcinoma in situ and invasive breast cancer. During this time all patients treated with mastectomy were offered IBR regardless of tumour stage. Results: Follow‐up data from 253 consecutive patients with IBR were reviewed. Patients with incomplete follow‐up data and those undergoing SSM for recurrent disease following previous lumpectomy were disregarded, leaving 207 for analysis. Offering IBR to all women requiring mastectomy resulted in a large proportion of patients with advanced disease. During a median follow‐up of 119 months, 17 (8·2 per cent) locoregional, six (2·9 per cent) local and 22 (10·6 per cent) distant recurrences were detected; the overall recurrence rate was 39 (18·8 per cent). Overall recurrence rate was associated with axillary lymph node metastasis ( P = 0·009), higher stage ( P < 0·001) and higher tumour grade ( P = 0·031). The breast cancer‐specific survival rate was 90·8 per cent (19 of 207 women died from recurrence). Conclusion: Based on these long‐term follow‐up data, SSM combined with IBR is an oncologically safe treatment option regardless of tumour stage. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.